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GEMOXAbstract Background: Patients with platinum-resistant epithelial ovarian cancer (EOC) experi-
ence poor outcome. Currently, no clearly superior management strategy exists for platinum-
resistant EOC patients.
Purpose: Analyze the efﬁcacy and safety of gemcitabine–oxaliplatin (GEMOX) in platinum resis-
tant EOC patients.
Patients and methods: Thirty-two patients with platinum-based resistant EOC were included. Stud-
ied patients had received GEM at the dose of 1000 mg/m2 on days 1 and 8 and OX 100 mg/m2 on
day 1, administered over 2 h 30 min after GEM infusion of 3 week treatment cycle.
Results: In the evaluation of tumor response, none of patients had achieved CR while PR, SD,
were observed in 7 (21.9%), 9 (28.1%) respectively, clinical beneﬁt (CR+ PR+ SD) was recorded
in 50% of patients while PD was observed in 16 (50%) patients. In regard to survival, the median
value of OS was 10.5 months (range, 2.2–17.5 months). The median value of PFS was 6.37 months
(range, 1–17.5 months). The one-year OS rate was 34.4% and the one-year PFS rate was 12.5%.
Concerning hematological toxicity grade 3 neutropenia was recorded in 4 (12.5%) patients while
grade 4 febrile neutropenia was recorded in 2 (6.3%) patients and grade 4 anemia was represented
by 3.1%. Grade 1–2 fatigue was the most common non-hematological toxicity and represented by
65.6% of patients. Grade 3 non hematological toxicity was recorded with nausea/vomiting and hep-
atic toxicity represented by 3.1% for both.
Conclusion: The GEMOX combination is a regimen with a moderate therapeutic efﬁcacy and tol-
erable toxic side effects in patients with platinum-resistant EOC.
 2016 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Ovarian cancer is the seventh most common cancer accounting
for nearly 4% of all new cases of cancer in women. This cancer
is usually fatal, and is the eighth most common cause of cancer
deaths in women worldwide [1,2].
In Egypt, one of the important regional registries is Ghar-
bia Population Based Cancer Registry (GPBCR), according
to its publications over a three year period (2000–2002), 225
ovarian cancer cases were registered with an average of 75
cases per year. They represented 2.2% of all incident cancers
accounting for 4.4% of all newly diagnosed female cancers
[3]. The other important regional registry in Egypt is Aswan
regional registry, in which over the year 2008, thirty-ﬁve cases
of ovarian cancer were registered, representing 5.6% of all
female cancer cases [4]. The majority of the women about
75% are diagnosed with advanced stage diseases that are
FIGO III or IV and overall survival rate for 5 years is about
40% [5–7]. The application of cytoreductive surgery followed
by platinum-based chemotherapy, with or without the addition
of a taxane is the most accepted treatment for advanced EOC
[2,8]. Record reveals that approximately 75% of these patients
attain complete clinical remission after the initial treatment [9].
Despite this fact, the majority of women with advanced EOC
will ultimately relapse with 20% of these patients with
platinum- and taxane-resistant disease [10,11].
Re treatment with a platinum compound in the platinum
‘‘sensitive” subgroup, i.e. patients recurring after 12 months
from the end of a platinum-based chemotherapy, yields
response in up to 70% of cases. Conversely, in platinum ‘‘resis-
tant” or ‘‘refractory” patients, the administration of agents
such as liposomal doxorubicin, topotecan, gemcitabine,
vinorelbine, docetaxel, etoposide, ifosfamide, and oxaliplatin,
is associated with a response rate ranging from 10% to 33%,
with a median PFS of 3–7 months [12,13]. However, the actual
beneﬁts of currently available treatment options in these
patients are poorly documented, particularly beyond the
second-line [12,14].
Oxaliplatin (OX) is a platinum derivative, diaminocyclo-
hexane platinum which has exhibited activities contrary to dif-
ferent types of tumors with a symmetrical mechanism of
impact like that of classic platinum drugs showing a different
toxicity proﬁle. Cisplatin or carboplatin seems not to be
cross-resistant with OX in human ovarian cell lines. As single
agent at 130 mg/m2 every three weeks, the objective response
rates range from 16% to 29% in patients treated after failure
of one or two regimens [9,15,16]. Gemcitabine (GEM; 2,2-
diﬂuorodeoxycitidine), a synthetic nucleoside analog of cyti-
dine, inhibits the S-phase of the cellular cycle. Several trials
have conﬁrmed its efﬁcacy in ovarian cancer patients, with
response rates up to 22% in platinum-resistant disease and a
median response duration ranging from 4 to 10 months. This
drug is usually well tolerated, with non-cumulative myelotoxi-
city being the dose-limiting toxicity [12–14].
The GEMOX combination was ﬁrst investigated by Faivre
et al. showing synergistic effects in human cell lines [17]. A
dose-ﬁnding combination trial proved feasibility and activity
in ovarian cancer patients and phase II trials conﬁrmed its efﬁ-
cacy in recurrent disease, with responses ranging from 9.5% to
37%, median PFS between 4.6 and 7.1 months, and an overall
acceptable toxicity [18–20]. Based on the above mentionedinformation we decided to conduct a retrospective study on
platinum pre-treated resistant EOC patients to determine the
efﬁcacy and evaluate the toxicity of the combination of
GEMOX regimen.Patients and methods
Patients
Patients’ data for this retrospective study were collected from
Clinical Oncology Department, Tanta University Hospital
during the period between December 2010 and December
2014.
Patients were eligible for this study if they had histologi-
cally or cytologically conﬁrmed EOC with the following: (1)
age more than 18 years, (2) Eastern Cooperative Oncology
Group (ECOG) performance status (PS) less than or equal
to 2, (3) previously not treated with either GEM or OX, (4)
relapsing disease within 6 months after treated with at least
one or more lines of platinum-based chemotherapy (5) radio-
logical evidence of measurable lesions, (6) adequate baseline
bone marrow function ‘‘absolute neutrophil countP 1500/
ml, platelet countP 100.000/ml”, (7) adequate baseline hep-
atic function ‘‘serum bilirubin 6 2.0 mg/d, transaminase aspar-
tate aminotransferase, alanine transaminase 6 2.0 the upper
limit of institutional normal”, (8) adequate renal function ‘‘cre-
atinine 6 1.5 mg/dl”.
Patients were excluded if they had other malignancies,
peripheral neuropathy as grade greater than 2, increased level
of CA-125 was considered as the only indication of relapsing
diseases, having central nervous system metastasis, severe co-
morbid conditions, or lacked the ability to comply with the
requirements of the protocol. Medical records served with all
the clinical information of every patient. Disease status and
required important data concerning the patients including
tumor recurrence and patient death were provided from rou-
tinely maintained hospital registry.
Treatment plan
All patients received GEM at the dose of 1000 mg/m2 as a 100-
min i.v. infusion after dilution in 250 ml normal saline on days
1 and 8 and OX 100 mg/m2 on day 1, administered over 2 h
and 30 min after GEM infusion diluted in 250 ml of 5% glu-
cose. The ‘‘standard’’ antiemetic regimen included ondanse-
tron 16 mg, dexamethasone 8 mg given i.v. 30 min before
chemotherapy administration. Treatment was repeated every
21 days. Treatment was given for a minimum of two cycles
in the absence of disease progression, unacceptable toxicity
uncontrolled by conservative treatment or patient refusal.
Granulocyte colony-stimulating factor and erythropoietin
were used if febrile neutropenia or Grade 3 anemia was
recorded in the earlier course of chemotherapy.
Dose modifications
Toxicity was graded using the National Cancer Institute Com-
mon Toxicity Criteria version 2.0 [21]. Dose adjustments were
made for each agent if a distinction in toxicity could be made.
If both agents were believed to be causing toxicity, a dose
Table 1 Patients and tumor characteristics (n= 32).
Characteristics No. of patients %
Age (years)
Median: 52
Mean: 51.8 ± 8.8
Range: 37–68
Performance status (ECOG)
0 7 21.9
1 17 53.1
2 8 25
Histological grade
I 6 18.7
II 8 25
III 12 37.5
IV 3 9.4
Unknown 3 9.4
Histological type
Serous 22 68.7
Mucinous 1 3.1
Endometrioid 2 6.2
Clear cell 3 9.4
Poorly diﬀerentiated 2 6.3
Other/unknown 2 6.3
Number of disease sites
1 8 25
2 10 31.2
P3 14 43.8
Measurable lesion
<5 cm 21 65.6
P5 cm 11 34.4
No. of prior platinum-based regimens
1 23 71.9
2 9 28.1
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reduction was planned for grade (G) 4 neutropenia or febrile
neutropenia, G3-4 thrombocytopenia or other G3-4 extra-
hematological toxicities, and G2-3 neurotoxicity; in the case
of more severe neurotoxicity, treatment discontinuation was
planned. G-CSF administration was allowed in the case of
G4 neutropenia, along with its prophylactic use in subsequent
cycles. Treatment was discontinued in the case of disease pro-
gression, unacceptable toxicity, and treatment delay longer
than 2 weeks or patient refusal.
Evaluation of response
Prior to each cycle, patients’ history was taken and clinical
examination with assessment of PS, complete blood count,
CA 125 assay along with other blood biochemistries was per-
formed. Tumor response was assessed every two cycles by
repeating baseline assessment using imaging studies
(abdomino-pelvic CT scan or MRI, chest CT scan and
X-ray) according to the Response Evaluation Criteria in Solid
Tumors (RECIST) [22]. Complete response (CR) was deﬁned
as the disappearance of all lesions for at least four weeks. Par-
tial response and PD were deﬁned as a reduction of more than
30% and an increase of more than 20% in the sum of the long-
est diameters of lesions respectively.
Statistical methods
The primary end point was to analyze the efﬁcacy and safety of
GEMOX combination on platinum-based resistant EOC
patients. The main criterion for efﬁcacy was objective response
rate; secondary criteria were time to progression, and overall
survival. Our secondary objective was to determine the type,
severity, and frequency of adverse events associated with
GEMOX treatment in these patients.
For descriptive statistics of qualitative variables, the fre-
quency distribution procedure was run with the calculation
of the number of cases and percentages. Overall survival was
deﬁned as the time elapsed from initiation of treatment to
the date of death or date of last follow-up. The progression
free survival was estimated from initiation of treatment to
the documentation of disease progression or the date of last
follow-up. The duration of response was measured from the
time of initial documented response to the ﬁrst sign of disease
progression. Kaplan–Meier method was used to estimate sur-
vival and 95% conﬁdence interval.
A comparison of survival was performed by the log rank
test. Data were analyzed on a personal computer using SPSS
(Statistical Package for Social Scientists) version 15; Chicago,
Illinois, USA.Results
Patient’s characteristics
Thirty-two patients with platinum-based resistant EOC were
reviewed between December 2010 and December 2014. Patient
characteristics are detailed in Table 1. Median age was 52 years
(range, 37–68). Histologically, 22 (68.7%) patients werediagnosed with serous carcinoma and 10 (31.3%) patients with
non serous carcinoma.
Prior to administration of GEMOX treatment, 131 cycles
of prior chemotherapy were administered to all patients with
a median number of 3 cycles (range, 2–10 cycles). Twenty-
three (71.9%) patients received only one regimen of
chemotherapy and 9 (28.1%) patients received 2 regimens
among whom 78.1% had received carboplatin/paclitaxel regi-
men. Thereafter, a total of 128 cycles of GEMOX regimen
were administered to all patients with the median number of
4 cycles (range, 1–7 cycles). Due to hematological or non-
hematological toxicities 27.5% of the total cycles (range 1–5
cycles) was delayed more than 21 days and 23.4% of adminis-
tered cycles had to go through dose reduction. Five (15.6%)
patients discontinued treatment because of progressive disease
and adverse events related to treatment (see Table 2).
Response
In the evaluation of tumor response according to the RECIST
criteria for all patients with measurable disease, none of
patients achieved CR while PR, SD, and PD were observed
Table 3 Clinical response to chemotherapy.
Response No. of patients (n= 32) %
Complete response (CR) – –
Partial response (PR) 7 21.9
Stable disease (SD) 9 28.1
Clinical beneﬁt
(CR+ PR+ SD)
16 50
Progressive disease (PD) 15 46.9
Figure 1 Overall survival for all patients.
Figure 2 Progression free survival for all patients.
Table 2 Treatment characteristics.
Characteristics
Interval from previous treatment
(months)
Median 2.05
Range 0.8–5.2
Chemotherapy cycles delivered Median 4
Range 2–7
Total 128
Treatment duration (weeks) Median 12
Range 3–21
No. of cycles received by patients 2–3
cycles
14
(43.8%)
4–5
cycles
11
(34.3%)
6–7
cycles
7 (21.9%)
Percentage of cycles with
full dose for both drugs
76.6%
Percentage of cycles with
delay (>21 days)
27.5%
186 M. Elshebeiny, W. Almorsyin 7 (21.9%), 9 (28.1%), and 16 (50%) of patients respectively.
The total tumor response rate (CR + PR) was reported in
21.9% of patients and, the objective response rate was
recorded in 50% of patients (Table 3).
Survival and disease progression
The median duration of response was 3.3 months (range, 2–
18 months). After a median follow-up period of 10.5 months,
25 patients had died. In regard to survival, median value of
OS was 10.5 months (range, 2.2–17.5 months) with 95% CI,
(8.44–12.56). The median value of PFS was 6.3 months (range,
1–17.5 months) with 95% CI, (4.63–7.87). The one-year OS
rate was 34.4% and the one-year PFS rate was 12.5% (Figs. 1
and 2).
Toxicity
Concerning hematological toxicity grade 1–2 leukopenia
occurred in 17 (53.1%) patients while grade 1–2 anemia
occurred in 15 (46.9%) patients. Grade 3 neutropenia was
recorded in 4 (12.5%) patients and Grade 4 febrile neutropenia
was recoded in 2 (6.25%) patients. Grade 1–2 fatigue was the
most common non-hematological toxicity and represented by
65.62% of patients followed with grade 1–2 neurotoxicity
and diarrhea and represented by 34.4% for both. Grade 4
non hematological toxicity was not recorded (Table 4).Discussion
Platinum-resistant ovarian cancer represents a major challenge
to modern oncology. GEMOX is a combination regimen with
proven activity and overall tolerable toxicity both in pretreated
[19,20,23] and ﬁrst-line treated EOC patients [24]. In the set-
ting of recurrent, platinum-resistant disease, GEM has been
Table 4 Hematological and non-hematological toxicity.
Toxicity Grade 1
No (%)
Grade 2
No (%)
Grade 3
No (%)
Grade 4
No (%)
Hematological toxicity
Anemia 11 (34.4) 4 (12.5) 2 (6.3) 1 (3.1)
Leukopenia 12 (37.5) 5 (15.6) 2 (6.3) –
Neutropenia 9 (28.1) 3 (9.4) 4 (12.5) –
Thrombocytopenia 6 (18.7) 4 (12.5) 3 (9.4) –
Febrile neutropenia – – – 2 (6.3)
Non-hematological toxicity
Nausea/vomiting 9 (28.1) 5 (15.6) 1 (3.1) –
Diarrhea 8 (25.0) 3 (9.4) – –
Constipation 2 (6.3) 3 (9.4) – –
Hepatotoxicity 5 (15.6) 1 (3.1) 1 (3.1) –
Neurotoxicity 6 (18.7) 5 (15.6) – –
Fatigue 9 (28.1) 12 (37.5) – –
Infection 3 (9.4) 2 (6.3) – –
Hypersensitivity 3 (9.4) – – –
Mucositis 3 (9.4) – – –
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efﬁcacy and tolerability of GEM/paclitaxel combination,
reporting responses in up to 40% of paclitaxel-naı¨ve patients
[25]. The combination of GEM/topotecan was tested in phase
I–II trials, with some encouraging results even in resistant dis-
ease [26], while GEM/docetaxel combination offered a
response rate of 25% in platinum resistant patients [27].
The GEM/liposomal doxorubicin regimen was used mostly
in platinum resistant ovarian cancer patients, yielding response
rates ranging from 22% to 42.8%, and a median time to pro-
gression and OS from 2.7 to 7.7, and 8.4 to 17 months, respec-
tively [28–30]. Oral etoposide, vinorelbine, irinotecan provide
examples of further drugs variously combined with GEM in
recurrent, platinum resistant ovarian cancer, with response
rates between 10% and 30% [31].
The regimen used in the present trial is derived from the
phase I study conducted by Mavroudis et al. in patients with
advanced solid tumors with increasing doses of GE 1000–
1600 mg/m2 on days 1 and 8, combined with OX 60–120 mg/
m2 on day 8, repeated every 21 days. The dose-limiting toxici-
ties were grade 3–4 neutropenia, thrombocytopenia and asthe-
nia [18].
In the current study, overall response rate was 21.9% in
thirty-two patients with measurable disease. The median dura-
tion of response was 3.3 months (range, 2–18 months). In addi-
tion, clinical beneﬁt rate, including CR, PR, and SD was 50%.
In terms of survival and toxicity, GEMOX chemotherapy
showed an adequate survival beneﬁt (median PFS, 6.4 months
and median OS, 10.5 months), and its toxicity was acceptable
without treatment-related death. These ﬁndings indicate that
GEMOX chemotherapy is feasible as a second or third line
treatment for pretreated patients with platinum-resistant EOC.
For clariﬁcation of the efﬁcacy and toxicity of GEMOX
chemotherapy in the treatment of patients with platinum-
resistant EOC, we compared our results with previous relevant
studies. The current study showed response comparable to that
reported in Kalykaki et al. with an overall response rate of
18.5% for patients with platinum-resistant or -refractory
disease [23]. Also, Raspagliesi et al. reported overall response
rates of 20% for platinum resistant or refractory patients trea-ted with the GEMOX combination [19]. However in the cur-
rent study, overall response rate was lower than that
reported in previous studies by Harnett et al. (26%), Vici
et al. (37%) and Ray-Coquard et al. (37%) [32,33,20]. A pos-
sible explanation for the difference in tumor response between
the current study and the previously reported studies would be
the small number of studied patients, and the different regi-
mens of prior chemotherapy.
In addition, we found that the median PFS and OS were
similar between the current study and the three previous stud-
ies. Ray-Coquard et al. reported that the median PFS was
4.6 months and the median OS was 11.4 months in resistant
or refractory patients treated with GEMOX [20]. Vici et al.
reported that the median PFS was 6.8 months, and the median
OS was 16.5 months [33]. Also Kalykaki et al. reported that
the median overall survival for patients with platinum-
resistant or -refractory disease was 11 months (range, 0.5–
31.6 months). The median PFS was 5.9 (range, 0.5–
31.5 months) for patients with platinum-resistant or -
refractory disease [23].
The toxicity proﬁle of GEMOX combination in this study
was well tolerable and reversible. Hematological toxicities were
mild, 4 (12.5%) patients had G3–4 neutropenia and only 1
(3.1%) patient had febrile neutropenia. G3–4 anemia, leukope-
nia and thrombocytopenia were recorded in 9.4%, 6.2% and
9.4% respectively. Non-hematological toxicities were mainly
fatigue, nausea-vomiting, diarrhea and neurotoxicity and most
of them were limited to mild grades. By an analysis of other
studies of GEMOX in the treatment of patients with
platinum-resistant EOC it was seen that toxicity proﬁle
recorded among our patients was similar to that of most of
these studies and can be managed with conservative treatments
[19,20,23,32].Conclusions
The GEMOX combination is a regimen with a moderate ther-
apeutic efﬁcacy when compared to other regimens of both
drugs, with tolerable toxic side effects in patients with
platinum-resistant EOC. However, this retrospective analytical
study suggests the need for further evaluation since it was lim-
ited to a small number of patients which might contribute to
the design of future studies in evaluating its clinical utility.
As such, more elaborative, multicenter, prospective and ran-
domized controlled clinical studies with a large number of
patients are necessary to evaluate its therapeutic efﬁcacy and
toxicity for the treatment of platinum-resistant EOC. Despite
advances in chemotherapy regimens, current therapeutic
options for platinum resistant ovarian cancer patients are
inadequate. Immunotherapy offers a novel and promising
therapeutic strategy for treating ovarian tumors. Following
the demonstration of the immunogenicity of ovarian tumors,
multiple immunotherapeutic modalities have been developed.
Antibody-based therapies, immune checkpoint blockade, can-
cer vaccines, and chimeric antigen receptor-modiﬁed T cells
have demonstrated preclinical success and entered clinical
testing.
Future directions would include the evaluation of lines of
therapy with biologic agents driven by speciﬁc biologic targets
such as antiangiogenic agents, antifolate drugs, poly (ADP-
ribose) polymerase (PARP) inhibitors, mTOR inhibitors and
188 M. Elshebeiny, W. Almorsyimmune editing agents which could help direct therapy for
patients with ovarian cancer in the future.Conflict of interest
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